U.S. Patent 12,460,206: Inclisiran PCSK9 siRNA Scope, Claims, and Patent Landscape

U.S. Patent 12,460,206 covers a highly specific pharmaceutical composition containing an inclisiran-type double-stranded RNA interference agent directed against PCSK9. The independent claim requires the exact modified antisense and sense sequences, a ligand attached to the 3′ end of the sense strand, and a sterile aqueous solution. Claim 2 narrows the composition to subcutaneous use.

The patent is most relevant to Leqvio (inclisiran), marketed by Novartis. It is a composition patent directed to the drug substance and delivery format, not merely a broad PCSK9 target or general siRNA platform.

What drug does U.S. Patent 12,460,206 protect?

The claimed sequence corresponds to inclisiran, an siRNA therapeutic that reduces hepatic PCSK9 expression. Inclisiran is a chemically modified, double-stranded RNA molecule conjugated to a triantennary N-acetylgalactosamine, or GalNAc, ligand. The GalNAc ligand targets the asialoglycoprotein receptor on hepatocytes and enables liver-directed delivery after subcutaneous administration.

The relevant product is:

Item	Description
Brand	Leqvio
Active ingredient	Inclisiran sodium
Target	PCSK9 mRNA
Modality	Small interfering RNA
Delivery	GalNAc-conjugated, hepatocyte-targeted RNAi
Route	Subcutaneous injection
Sponsor/marketer	Novartis
FDA approval	December 22, 2021
Approved use	LDL-cholesterol reduction in specified patients with hypercholesterolemia

The sequence in claim 1 uses 2′-O-methyl and 2′-fluoro ribose modifications, phosphorothioate linkages, and a 2′-deoxythymidine residue. Those modifications are material limitations. A competing molecule that inhibits PCSK9 but uses different sequences or a materially different chemistry would not automatically fall within this claim.

What does claim 1 of U.S. Patent 12,460,206 require?

Claim 1 has five principal elements:

A pharmaceutical composition.
A double-stranded RNAi agent that inhibits PCSK9 expression in a cell.
The exact antisense strand identified as SEQ ID NO:1663.
The exact sense strand identified as SEQ ID NO:1657.
A ligand conjugated to the 3′ end of the sense strand, with the composition presented in a sterile aqueous solution.

The use of “comprising” for the pharmaceutical composition generally makes the claim open-ended as to additional excipients, buffers, stabilizers, tonicity agents, preservatives, or other formulation components. The sequence limitations are materially narrower because each strand is stated to “consist of” a specified nucleotide sequence.

Sequence and chemical limitations

The supplied claim defines the following chemistry:

Symbol	Required chemistry
a, c, g, u	2′-O-methyl A, C, G, and U
Af, Cf, Gf, Uf	2′-fluoro A, C, G, and U
s	Phosphorothioate linkage
dT	2′-deoxythymidine
X	Oxygen in the referenced conjugation schematic

These limitations distinguish the claim from a generic siRNA claim. A non-infringing product strategy could involve changing the passenger or guide sequence, altering sugar modifications, replacing selected phosphorothioate linkages, using a different conjugation position, or changing the ligand architecture. Each change would require a separate infringement and validity analysis because the patent may contain related claims in the same family.

The ligand identity is essential to the final scope. The claim text supplied here refers to a schematic that is not reproduced. Based on the known structure of inclisiran, the ligand is expected to be a hepatocyte-targeting GalNAc conjugate, but the precise number of GalNAc residues, linker atoms, stereochemistry, and attachment structure must be read from the issued patent drawing and specification before making a definitive ligand-level infringement conclusion.

What does claim 2 add?

Claim 2 depends on claim 1 and requires that the pharmaceutical composition be “for subcutaneous use.”

This limitation aligns the claim closely with the approved Leqvio product, which is administered by subcutaneous injection. Claim 2 is narrower than claim 1 because it adds a route-of-administration requirement. It may have greater practical relevance against a product using the same claimed siRNA and conjugate in a commercial injectable formulation.

A product containing the same sequence and conjugate but administered intravenously, intramuscularly, or by another route could fall outside claim 2 while remaining potentially relevant to claim 1. The phrase “for subcutaneous use” can also raise claim-construction questions regarding labeling, formulation suitability, and the manufacturer’s intended use.

How strong is the patent estate for inclisiran?

The patent represented by U.S. Patent 12,460,206 is strong against an exact-copy product because it combines several product-defining limitations:

The PCSK9 target.
The exact antisense sequence.
The exact sense sequence.
Defined nucleotide chemistry.
A 3′ sense-strand ligand conjugate.
A sterile aqueous formulation.
Subcutaneous use in dependent claim 2.

Its principal vulnerability is claim narrowness. A challenger does not necessarily need to invalidate the entire patent if it can design around one required element. The most commercially meaningful design-around variables are the ligand structure, conjugation site, linker, nucleotide modifications, and siRNA sequence.

Validity considerations

A validity challenge would likely focus on:

Anticipation by prior PCSK9 siRNA or inclisiran disclosures.
Obviousness based on earlier PCSK9 RNAi sequences and GalNAc delivery platforms.
Written description and enablement for the claimed chemical configuration.
Whether the exact sequence and conjugate were adequately disclosed before the relevant priority date.
Patent-term and prosecution-history issues.
Whether claim amendments created prosecution-history estoppel.

The exact-sequence limitations can improve validity by narrowing the claim, but they also create a potential written-description and obviousness record centered on the specific molecule.

What formulation patents are relevant to Leqvio?

Claim 1 covers a composition in a sterile aqueous solution, but it does not, on the supplied text, require a particular buffer, pH, concentration, vial, prefilled syringe, excipient, or storage condition. The claim therefore has broader formulation coverage than a claim limited to a named buffer or concentration, while remaining narrower than a claim covering all PCSK9 siRNA formulations.

Relevant formulation questions include:

Issue	Relevance
Sterile aqueous solution	Express limitation in claim 1
Subcutaneous injection	Express limitation in claim 2
GalNAc conjugation	Central product-identity limitation
Buffer and pH	Not specified in the supplied claims
Dose and concentration	Not specified in the supplied claims
Container or device	Not specified in the supplied claims
Lyophilized product	Potentially outside a claim requiring an aqueous solution at the claimed composition stage
Manufacturing process	Not covered by the supplied claims unless separately claimed in the patent family

Other family members may contain claims directed to conjugation chemistry, manufacturing, dosing schedules, patient populations, or specific formulations. A freedom-to-operate analysis must review the entire U.S. family, not only claims 1 and 2 of Patent 12,460,206.

What is the Orange Book status of inclisiran?

Leqvio is an FDA-approved small-molecule chemical drug product in the regulatory sense applicable to oligonucleotide medicines, not a biologic subject to the biosimilar pathway. Its approved labeling and listed patent information should be reviewed in the FDA Orange Book and the approved product labeling.

The relevant regulatory pathway is generally an abbreviated new drug application, or ANDA, for a generic equivalent, although a complex oligonucleotide product may create substantial pharmaceutical-equivalence, analytical, bioequivalence, and manufacturing questions. A 505(b)(2) application may also be considered for a product that differs in formulation, delivery system, or clinical use.

Orange Book listing does not itself establish patent validity or infringement. It determines which listed patents an ANDA applicant must address through a certification or notice process under the Hatch-Waxman framework.

The supplied information does not establish the complete Orange Book patent list, certification status, or the expiration date of every patent protecting Leqvio. Those data must be matched against the FDA’s current electronic Orange Book and the patent’s official prosecution record.

When does U.S. Patent 12,460,206 lose exclusivity?

The exact expiration date cannot be determined from the claim text alone. U.S. patent expiration normally depends on:

The earliest effective nonprovisional filing date in the priority chain.
Patent-term adjustment.
Terminal disclaimers.
Patent-term extension, if granted.
Patent-term restoration or other statutory adjustments.
Any continuation or divisional relationship affecting the patent term.

For a utility patent filed after June 8, 1995, the ordinary term is 20 years from the earliest effective U.S. nonprovisional filing date, subject to adjustment under 35 U.S.C. §§ 154 and 156. The issue date of U.S. Patent 12,460,206 is not sufficient by itself to calculate expiration.

Commercial exclusivity also differs from patent exclusivity. Leqvio may have FDA regulatory exclusivity, pediatric exclusivity, orphan-drug exclusivity, or other periods separate from patent term. The applicable period must be confirmed from the FDA approval record and Orange Book.

Are Paragraph IV challenges likely for inclisiran?

A Paragraph IV challenge could arise when an ANDA applicant asserts that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic. For a product claim like claim 1, an ANDA applicant would need to address the exact sequence, modifications, ligand conjugation, and sterile aqueous composition.

Potential challenger positions include:

The proposed product does not use the claimed ligand.
The ligand is attached at a different position.
One or more nucleotide modifications differ.
The product does not contain the claimed exact sequences.
The product is not a sterile aqueous composition within the claim.
The patent is invalid for anticipation or obviousness.
The patent is unenforceable because of inequitable conduct or prosecution-related issues.

An ANDA applicant may also file a Paragraph III certification and defer launch until patent expiry rather than litigate. A 505(b)(2) applicant could face a different patent-certification and litigation posture depending on the proposed labeling and product differences.

No Paragraph IV litigation, settlement agreement, or generic launch date can be confirmed from the supplied claim text alone.

Is there biosimilar risk for inclisiran?

Inclisiran does not present conventional biosimilar risk because it is not regulated as a therapeutic biologic under the Public Health Service Act. The principal competitive risk is from:

Generic or follow-on oligonucleotide products.
505(b)(2) products with different formulations or delivery systems.
Alternative PCSK9 therapies.
Competing RNAi products.
Monoclonal antibodies such as evolocumab and alirocumab.
Oral lipid-lowering therapies, including statins, ezetimibe, and newer agents.

The scientific and regulatory complexity of demonstrating equivalence for a GalNAc-conjugated siRNA may delay entry even after a patent expires. Analytical comparability, impurity profiles, conjugate characterization, tissue distribution, pharmacodynamic response, and immunogenicity may be important development barriers.

How does the patent compare with competing PCSK9 therapies?

Product	Modality	Target	Administration	Principal competition
Leqvio	GalNAc-siRNA	PCSK9 mRNA	Subcutaneous, infrequent dosing	Patent and formulation barriers
Repatha	Monoclonal antibody	Circulating PCSK9	Subcutaneous	Biologic exclusivity and biosimilar pathway
Praluent	Monoclonal antibody	Circulating PCSK9	Subcutaneous	Biologic and patent estate
Statins	Small molecules	Cholesterol synthesis	Oral	Low cost and established use
Ezetimibe	Small molecule	Intestinal cholesterol absorption	Oral	Generic competition
Bempedoic acid	Small molecule	ATP citrate lyase	Oral	Small-molecule competition

Patent 12,460,206 has a narrower chemical scope than a platform patent but a closer relationship to the marketed product. Its commercial value therefore depends on whether it covers the product as actually manufactured and sold, and whether other patents provide overlapping protection after this patent expires.

What manufacturing and intellectual-property barriers affect generic entry?

The highest barriers are likely to be:

Reproducing the precise modified siRNA sequence.
Controlling phosphorothioate stereochemistry and impurity profiles.
Manufacturing the GalNAc ligand and linker.
Achieving consistent 3′-end conjugation.
Demonstrating sterile injectable quality.
Establishing equivalence for a complex oligonucleotide.
Validating subcutaneous pharmacodynamic performance.
Obtaining sufficient commercial-scale manufacturing capacity.

These barriers do not extend patent term, but they can affect launch timing and investment requirements. A competitor may pursue a different PCSK9 sequence or ligand as a design-around, but that approach would require new clinical, analytical, and regulatory development.

What is the commercial risk profile for Novartis?

The patent is commercially relevant because it protects a product-specific configuration associated with Leqvio rather than a broad research platform. Risk increases if:

The patent is listed in the Orange Book.
The patent has a late expiration date.
Other family patents cover the same sequence or conjugate.
The patent has patent-term adjustment or extension.
Novartis has additional method-of-use or formulation patents.
No validated alternative GalNAc-siRNA manufacturing route exists.

Risk decreases if:

The ligand limitation is narrow.
Competitors can change the ligand or conjugation site without losing clinical performance.
Earlier patents expire before the product claim.
A generic applicant can establish non-infringement through a sequence or chemistry modification.
The patent family contains terminal disclaimers or overlapping claims with limited remaining term.

Key Takeaways

U.S. Patent 12,460,206 claims an inclisiran-type PCSK9 siRNA composition.
Claim 1 requires exact antisense and sense sequences, specified chemical modifications, a 3′ sense-strand ligand conjugate, and a sterile aqueous solution.
Claim 2 adds subcutaneous use and is closely aligned with Leqvio’s approved administration.
The claim is strong against an exact-copy product but narrow enough to create design-around opportunities.
The ligand schematic is essential for determining the precise infringement scope.
Inclisiran is not subject to conventional biosimilar competition; generic and 505(b)(2) pathways are more relevant.
Exact patent expiration, Orange Book listings, Paragraph IV activity, litigation, and settlement status require review of the official patent and FDA records.
Manufacturing complexity may delay follow-on entry even after patent or regulatory exclusivity ends.

FAQs

Does Patent 12,460,206 cover all PCSK9 siRNA drugs?

No. It requires the specific sequences, chemical modifications, ligand conjugation, and sterile aqueous composition recited in claim 1.

Does a different GalNAc ligand avoid Patent 12,460,206?

Potentially, but only if the alternative ligand or conjugate falls outside the claim and no doctrine-of-equivalents or related-family claim applies.

Does claim 2 cover every subcutaneous PCSK9 treatment?

No. Claim 2 depends on claim 1 and therefore retains all of claim 1’s sequence, chemistry, ligand, and formulation limitations.

Can an oligonucleotide competitor use the same PCSK9 target without infringing?

Possibly. A competitor using a different sequence or materially different chemical structure may avoid this particular composition claim, subject to other patents in the relevant family or competing patent estates.

Is Leqvio exposed to generic competition after this patent expires?

Potentially. Entry would still depend on the complete Orange Book patent landscape, regulatory pathway, product equivalence requirements, manufacturing capability, and any unexpired formulation, method-of-use, or process patents.

References

U.S. Patent No. 12,460,206, claims 1-2. United States Patent and Trademark Office.
U.S. Food and Drug Administration. (2021). Leqvio (inclisiran) prescribing information.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations.
U.S. Food and Drug Administration. (2022). Product-specific guidance for generic drug development relating to complex drug products.
United States Patent and Trademark Office. (n.d.). Patent term adjustment and patent term extension resources.
Novartis AG. (2024). Annual report.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Novartis	LEQVIO	inclisiran sodium	SOLUTION;SUBCUTANEOUS	214012-001	Dec 22, 2021		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial	Y	Y			⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	2929031	⤷ Start Trial	301107	Netherlands	⤷ Start Trial
European Patent Office	2929031	⤷ Start Trial	PA2021510	Lithuania	⤷ Start Trial
European Patent Office	2929031	⤷ Start Trial	2021C/520	Belgium	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 12,460,206

Which drugs does patent 12,460,206 protect, and when does it expire?

Summary for Patent: 12,460,206